Brecanavir
From Wikipedia, the free encyclopedia
|
Brecanavir
|
|
| Systematic (IUPAC) name | |
| ? | |
| Identifiers | |
| CAS number | ? |
| ATC code | ? |
| PubChem | ? |
| Chemical data | |
| Formula | C33H41N3O10S2 |
| Mol. mass | ? |
| Pharmacokinetic data | |
| Bioavailability | ? |
| Metabolism | ? |
| Half life | ? |
| Excretion | ? |
| Therapeutic considerations | |
| Pregnancy cat. |
? |
| Legal status | |
| Routes | ? |
Brecanavir (INN; codenamed GW640385) is a protease inhibitor which has been studied for the treatment of HIV.[1]
On December 2006, its developer, GlaxoSmithKline discontinued further development because of insurmountable issues regarding formulation.[2]
[edit] References
- ^ Hazen R, Harvey R, Ferris R, et al (September 2007). "In vitro antiviral activity of the novel, tyrosyl-based human immunodeficiency virus (HIV) type 1 protease inhibitor brecanavir (GW640385) in combination with other antiretrovirals and against a panel of protease inhibitor-resistant HIV". Antimicrob. Agents Chemother. 51 (9): 3147–54. doi:. PMID 17620375.
- ^ GlaxoSmithKline (2006-12-18). "GlaxoSmithKline discontinues clinical development of investigational protease inhibitor brecanavir (640385)". Press release. Retrieved on 2008-06-11.
|
|||||||||||||||||||||||||||||

